Codexis, a biotech company specializing in enzymatic solutions for manufacturing oligonucleotide therapeutics, announced it priced a public offering of 16,666,667 shares at $1.50 each. The offering is expected to raise net proceeds of approximately $23.1 million, which Codexis plans to use for working capital, research, development, and general corporate purposes. The offering is set to close around July 27, 2026, with underwriters having the option to purchase an additional 2.5 million shares. This capital raise supports Codexis' efforts to advance its enzymatic manufacturing platform and expand its business activities.
Cadillac Mines Corporation announced the pricing and upsizing of its initial public offering (IPO) to approximately CA$385 million, selling 47.1 million common shares at CA$6.90 each and 6.3 million special accretive shares at CA$9.52 each. The incre...
Cadillac Mines Corporation has priced and upsized its initial public offering to $385 million, selling 47.1 million common shares at $6.90 each and 6.3 million special flow-through shares at $9.52 each. The offering includes a treasury sale raising a...
Coinbase has launched support for Injective's native INJ token, enabling users to trade, deposit, and withdraw the token directly on the exchange. This update allows transfers on Injective's own network, enhancing user control and flexibility beyond ...
Silgan Holdings is maintained at a 'hold' rating due to revenue growth being offset by stagnant profits and cash flows. Although the company's valuation appears cheap, it is not attractive compared to its packaging industry peers, limiting potential ...
Bitcoin remained stable around $65,400 during Asian trading despite a massive $797 billion drop in value among major U.S. tech stocks, known as the Magnificent Seven, due to concerns over heavy AI infrastructure spending. This selloff dragged the S&P...
